Working to facilitate rapid translation of scientific discoveries into therapeutics

Request for Proposals for Future meetings

Call for expression of interest to host Annual EUSTM Conferences 2020 & 2021

The European Society for Translational Medicine (EUSTM) is a neutral global healthcare organization whose principal objective is to enhance world-wide healthcare by facilitating rapid translation of scientific discoveries into therapeutics. EUSTM run two annual conference series 1) Clinical & Translational Medicine 2) Clinical Congress. The EUSTM conferences provide a core forum for dissemination of ground-breaking research and clinical developments under specified conference themes (set each year). The EUSTM conferences unite scientists, clinicians, public health professional, world leaders and experts from research institutions, pharma, biotech industry, regulatory agencies, policy makers, and governments.

The current practice is to hold annual conferences in European countries, however due to rapid growth of conferences and global nature of delegates, the EUSTM Board of Directors has expressed the desire to consider Non-EU Hosts along with EU hosts. The Board is responsible for selecting a site that is financially viable option for the organization. The Society depends on income from annual conferences for a major part of its operating budget. Since a significant part of that income originates from corporate exhibits and support sales that are generated through the conference, the ability of the local host sponsor to generate handsome profit and to recruit conference delegates becomes an important factor in site selection.

The proposal may be prepared by the city conference bureau or a professional Congress Organizer, but in either case it must be supported by a local host Sponsor (University, Hospital, Research Institution, national association/society/organization). For 2020 Congress, the local host sponsor must be well-reputed and actively engaged in Oncology/Cancer or Hematology research and/or clinical services in the region. For Joint EU-continent or/and for 2021 Congress, local sponsor can be from any clinical theme (Cardiology/Surgery/Diabetes/Others). The local sponsor should be financially strong and able to generate funds from various sources (industry, institutional, government, local city/region, in-kind support, income from exhibition).

In the case the host is located in a different continent, a ‘Joint EU-Host Continent conference’ title will be considered. The objective of such congress would be to provide updated scientific/clinical knowledge to the local region with special adaption to local needs. In addition, if the proposal is strong, it may also be considered for a separate EUSTM Clinical Congress Series (in the area of interest of local sponsor). A discounted registration fee will be charged to that region delegates.

2020: 7th Annual Clinical & Translational Medicine Congress on Blood Cancers/Hematology Malignancies

Deadline for Bid Proposal: 10 December 2019

Conference Months: October-December 2020

Duration: 3 Days

Expected Size: 250

2021: 8th Annual Clinical & Translational Medicine Congress on (Theme Pending; Open for Suggestion. Cardiology/Surgery/Diabetes/Others)

Deadline for Bid Purposal: 15 June 2020

Conference Month: October-December 2021

Duration: 3 Days

Expected Size: 250

Benefits for co-sponsor

In exchange for financial support of the annual meeting the co-sponsor will be positioned as the co-sponsor/co-organizer in the years leading up to the conference and during the conference. The co-sponsor will receive recognition and benefits that are mutually agreed upon. As desired, the conference will provide visibility and coverage at national/regional level to the local sponsor.

In case the host is in a different continent, a ‘Joint EU-Host Continent conference’ title will help to highlight local sponsor institution’s work and visibility at the global level. If proposal is strong, it may also be considered for a separate EUSTM Clinical Congress series (in the area of interest of local sponsor).

EUSTM minimum requirements for co-sponsorship and site selection

Each proposal will be evaluated based upon the destination’s ability to meet these minimum criteria:

  • The co-sponsoring organization must have an active presence in the field of Oncology/Cancer or Hematology research and/or clinical services in the region.
  • The local sponsor should be capable of active marketing and dissemination strategies in order to generate conference delegates from their region.
  • The co-sponsoring organization must show that it has the capacity to provide the financial support, including the source of funds from additional associated sources as necessary, and it must be able to commit sponsorship funds prior to required venue deposits. Please provide an explanation of how the co-sponsoring organization will fund the meeting support and provide a dollar amount of support to be offered. If government or foundation funds are to be used, provide a list of any restrictions that may pertain to the use of these funds.

Considerations

  • Issues that will be assessed by the staff and Board of Directors include ability of local sponsor to generate sufficient finances and audience for the conference.
  • EUSTM will look at factors such as the number of potential registrants and speakers that can be drawn from the region, accessibility to major modes of travel, and potential synergies and intangible benefits that may be created between EUSTM and the regional organization as a result of the meeting.
  • The EUSTM Scientific Program Committee has sole discretion in speaker and abstract poster selection. EUSTM also exercises sole discretion in the selection of all Scientific Program Committee members, but accepts suggestions for committee members from the host region, and, as a matter of policy, selects members from the host region.
  • The EUSTM retains sole discretion on meeting revenue. Revenue sharing with co-sponsors is not permissible.
  • EUSTM staff will require a site visit to all locations being considered. These efforts are often sponsored and coordinated by a local or national Tourism Board. A meeting with the local bid committee is customary during these site visits.

Letter of intent for co-sponsorship

As a first step, please send a letter of intent for co-sponsorship from the local bid office as part of the process for selecting which locations to consider. The letter should be addressed to President, EUSTM (Prof. Dr Aamir Shahzad: aamir.shahzad@eutranslationalmedicine.org) and dated on or before 2nd December 2019. Co-sponsor letters of intent should include a brief outline of the proposed co-sponsors and their involvement in the Conference theme, and outline their proposed financial support along with sources.

Full proposal

Proposals should be addressed to the EUSTM Board of Directors and email to President, EUSTM (Prof. Dr Aamir Shahzad: aamir.shahzad@eutranslationalmedicine.org)

There is no defined limit to the number of pages that may be included in a proposal, but the Board appreciates succinct descriptions and rationales.

Full proposals will be received until 10 December 2019.

Office

European Society for Translational Medicine (EUSTM)
Schwindgasse 4/7
1040, Vienna, Austria
+43 1 8923 562
info@eutranslationalmedicine.org
www.eutranslationalmedicine.org

Previous Events


  • EUSTM-2019


  • ECC-2019


  • EUCCR-2018


  • EUCCR-2017


  • EUSCR-2017


  • EUSTM-2017


  • EUSTM-2016


  • EUSTM-2015

2013-2019©European Society for Translational Medicine (EUSTM)

Subscribe to Our Newsletter